Massachusetts Financial Services Co. MA Trims Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Massachusetts Financial Services Co. MA lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 97.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 15,234 shares of the biopharmaceutical company's stock after selling 499,031 shares during the quarter. Massachusetts Financial Services Co. MA's holdings in Regeneron Pharmaceuticals were worth $10,852,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth $802,036,000. Amundi boosted its position in Regeneron Pharmaceuticals by 45.8% during the fourth quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the period. Loomis Sayles & Co. L P increased its stake in shares of Regeneron Pharmaceuticals by 33.4% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock worth $1,122,168,000 after purchasing an additional 393,997 shares in the last quarter. Proficio Capital Partners LLC raised its position in shares of Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock valued at $156,284,000 after purchasing an additional 219,162 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Regeneron Pharmaceuticals by 6.8% during the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after buying an additional 155,369 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company's stock.

Remove Ads

Regeneron Pharmaceuticals Trading Up 1.4 %

Shares of REGN traded up $7.79 during trading hours on Friday, hitting $554.18. The company had a trading volume of 1,170,894 shares, compared to its average volume of 707,547. Regeneron Pharmaceuticals, Inc. has a 52-week low of $525.99 and a 52-week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock's 50 day moving average price is $659.94 and its 200 day moving average price is $755.22. The firm has a market cap of $60.59 billion, a P/E ratio of 14.48, a P/E/G ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the previous year, the firm earned $11.86 EPS. The business's quarterly revenue was up 10.3% on a year-over-year basis. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.64%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 2.30%.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Citigroup reduced their price objective on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Bernstein Bank decreased their price objective on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. UBS Group downgraded Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their target price for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Robert W. Baird reduced their target price on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a report on Wednesday, February 5th. Finally, BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.